Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype?

Hormones and Cancer

Volumn 2, Issue 1, 2011, Pages 47-61

  Maitland, Norman J ^a   Frame, Fiona M ^a   Polson, Euan S ^a   Lewis, John L ^a   Collins, Anne T ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Basal; Differentiation; Luminal; Prostate; Stem cells

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROBASIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P63;

ANIMAL CELL; ARTICLE; BASAL CELL; CANCER STEM CELL; CASTRATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL SELECTION; EPITHELIUM CELL; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TMPRSS2 GENE; TUMOR RECURRENCE; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; NEOPLASTIC STEM CELLS; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 78751569615     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-010-0058-y     Document Type: Article

References (77)

1. Maitland NJ (2008) Pathobiology of the human prostate. Trends Urol Gynaecol Sex Health 13: 12-19.
2. Gutman EB, Sproul EE, Gutman AB (1936) Significance of increased phosphatase activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 28: 485-495.
3. Vickers AJ, Cronin AM, Roobol MJ, Hugosson J, Jones JS, Kattan MW, Klein E, Hamdy F, Neal D, Donovan J, Parekh DJ, Ankerst D, Bartsch G, Klocker H, Horninger W, Benchikh A, Salama G, Villers A, Freedland SJ, Moreira DM, Schröder FH, Lilja H (2010) The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res 16(17): 4374-4381.
4. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M (2010) Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16(1): 203-211.
5. Miller GJ, Cygan JM (1994) Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 152: 1709-1713.
6. Sadi MV, Barrack ER (1993) Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 71: 2574-2803.
7. Ruijter ET, Miller GJ, van de Kaa CA et al (1999) Molecular analysis of multifocal prostate cancer lesions. J Pathol 18: 271-277.
8. Lydiatt WM, Anderson PE, Bazzana T, Casale M, Hughes CJ, Huvos AG, Lydiatt DD, Schantz SP (1998) Molecular support for field cancerization in the head and neck. Cancer 82(7): 1376-1380.
9. Macintosh CA, Stower M, Reid N, Maitland NJ (1998) Precise microdissection of human prostate cancers reveals genotypic heterogeneity. Cancer Res 58(1): 23-28.
10. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P, Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper CS (2008) Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27(14): 1993-2003.
11. Tomlins SA et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748): 644-648.
12. Lin B, Ferguson C, White JT, Wang S, Vessella R, True LD, Hood L, Nelson PS (1999) Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 59(17): 4180-4184.
13. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10(2): 177-188.
14. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, Alimonti A, Nardella C, Varmeh S, Scardino PT, Cordon-Cardo C, Gerald W, Pandolfi PP (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 41(5): 619-624.
15. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N, Chinnaiyan AM (2009) Induced chromosomal proximity and gene fusions in prostate cancer. Science 326(5957): 1230.
16. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG (2009) Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6): 1069-1083.
17. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3(7): 730-737.
18. Boman BM, Wicha MS (2008) Cancer stem cells: a step toward the cure. J Clin Oncol 26(17): 2795-2799.
19. Maitland NJ, Collins AT (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26(17): 2862-2870.
20. Stanley JR, Woodley DT, Katz SI, Martin GR (1982) Structure and function of basement membrane. J Invest Dermatol 79(Suppl 1): 69s-72s.
21. Lang SH, Stark M, Collins A, Paul AB, Stower MJ, Maitland NJ (2001) Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth Differ 12(12): 631-640.
22. Yang F, Strand DW, Rowley DR (2008) Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma. Oncogene 27(4): 450-459.
23. Cunha GR (1984) Androgenic effects upon prostatic epithelium are mediated via trophic influences from stroma. Prog Clin Biol Res 145: 81-102.
24. Berry PA, Maitland NJ, Collins AT (2008) Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol 288(1-2): 30-37.
25. Thomson AA (2008) Mesenchymal mechanisms in prostate organogenesis. Differentiation 76(6): 587-598.
26. Leong KG, Wang BE, Johnson L, Gao WQ (2008) Generation of a prostate from a single adult stem cell. Nature 456(7223): 804-808.
27. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461(7263): 495-500.
28. Collins AT, Habib FK, Maitland NJ, Neal DE (2001) Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 114(Pt 21): 3865-3872.
29. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON (2010) Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate 70(5): 491-501.
30. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117(Pt 16): 3539-3545.
31. Meregalli M, Farini A, Belicchi M, Torrente Y (2010) CD133(+) cell isolated from various sources and their role in future clinical perspectives. Expert Opin Biol Ther 10(11): 1521-1528.
32. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
33. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
34. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
35. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 67(14): 6796-6805, Erratum in: Cancer Res. 2007 Sep 15; 67(18): 8973.
36. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT (2008) The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 68(23): 9703-9711.
37. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, Hamdy FC, Eaton CL, Thalmann GN, Cecchini MG, Pelger RC, van der Pluijm G (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 70(12): 5163-5173.
38. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB (2008) Farrar WL. CD44+CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98(4): 756-765.
39. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci USA 107(6): 2610-2616.
40. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, Wion D (2007) Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258(2): 286-290.
41. Shmelkov SV, St Clair R, Lyden D, Rafii S (2005) AC133/CD133/prominin-1. Int J Biochem Cell Biol 37(4): 715-719.
42. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry PA, Hyde CF, Lewis JL, Stower MJ, Maitland NJ, Collins AT (2008) Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9(5): R83.
43. Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol 153(3): 911-919.
44. Grisanzio C, Signoretti S (2008) p63 in prostate biology and pathology. J Cell Biochem 103(5): 1354-1368.
45. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62(8): 2220-2226.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4): 704-715.
47. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J (2008) Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 68(4): 989-997.
48. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Gordon Bryden AA, Villette JM, Stower MJ, Maitland NJ (2002) Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 52: 253-263.
49. Hager S, Frame FM, Collins AC, Burns JE, Maitland NJ (2008) An internal polyadenylation signal substantially increases expression levels of lentivirus-delivered transgenes but has the potential to reduce virus titre in a promoter-dependent manner. Hum Gene Ther 19: 840-850.
50. Frame FM, Hager S, Pellacani D, Stower MJ, Walker HF, Burns JE, Collins AT, Maitland NJ (2010) Development and limitations of lentivirus vectors as tools for tracking differentiation in prostate epithelial cells. Exp Cell Res 316(19): 3161-3171.
51. Kraaij R, van der Weel L, de Ridder CM, van der Korput HA, Zweistra JL, van Rijswijk AL, Bangma CH, Trapman J (2007) A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors. Prostate 67(8): 829-839.
52. Yan Y, Sheppard PC, Kasper S, Lin L, Hoare S, Kapoor A, Dodd JG, Duckworth ML, Matusik RJ (1997) Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 32(2): 129-139.
53. Swift SL, Burns JE, Maitland NJ (2010) Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res 70(1): 347-356.
54. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69(6): 2305-2313.
55. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1): 16-22.
56. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8): 2715-2730.
57. McPherson SJ, Hussain S, Balanathan P, Hedwards SL, Niranjan B, Grant M, Chandrasiri UP, Toivanen R, Wang Y, Taylor RA, Risbridger GP (2010) Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 107(7): 3123-3128.
58. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 100(11): 815-825.
59. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010) Identification of a cell of origin for human prostate cancer. Science 329(5991): 568-571.
60. Collins AT, Maitland NJ (2009) Prostate cancer: regeneration of interest in the prostate. Nat Rev Urol 6(4): 184-186.
61. Seita J, Weissman IL (2010) Hematopoietic stem cell: self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2(6): 640-653.
62. Sugimura Y, Cunha GR, Donjacour AA (1986) Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod 34(5): 973-983.
63. Fink D, Fazli L, Aronow B, Gleave ME, Ong CJ (2006) Clusterin is not essential for androgen-regulated involution and regeneration of the normal mouse prostate. Prostate 66(13): 1445-1454.
64. Han G, Buchanan G, Ittmann M, Harris JM, Yu X, Demayo FJ, Tilley W, Greenberg NM (2005) Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 102(4): 1151-1156.
65. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92(8): 3439-3443.
66. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H (2009) Lin-Sca-1+ CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 69(22): 8555.
67. Liao CP, Adisetiyo H, Liang M, Roy-Burman P (2010) Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70(18): 7294-7303.
68. Kurita T, Medina RT, Mills AA, Cunha GR (2004) Role of p63 and basal cells in the prostate. Development 131: 4955-4964.
69. Weinstein MH, Signoretti S, Loda M (2002) Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol 15(12): 1302-1308.
70. Vander Griend DJ, D'Antonio J, Gurel B, Antony L, Demarzo AM, Isaacs JT (2010) Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 70(1): 90-99.
71. Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL (2008) Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Prostate 68(9): 1007-1024.
72. Li H, Chen X, Calhoun-Davis T, Claypool K, Tang DG (2008) PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Res 68(6): 1820-1825.
73. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K, Coghlan L, Tang DG (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25(12): 1696-1708.
74. Gu G, Yuan J, Wills M, Kasper S (2007) Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67(10): 4807-4815.
75. van Weerden WM, Bangma C, de Wit R (2009) Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 100(1): 13-18.
76. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, Gout PW, Squire JA, Cunha GR, Wang YZ (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85(11): 1392-1404.
77. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7): 3983-3988.